Although the molecular mechanisms underlying the association between REV-ERBα and Fas remain to be further investigated, the present study suggests that REV-ERBα agonist, including GSK4112, might have therapeutic benefits in Fas-associated hepatic disorders. The gene discussed is NR1D1; the disease is liver disorder.